Merck, Pfizer Settle Vaccine Patent Infringement Litigation

Merck, Pfizer enter settlement agreement on patent infringement litigation related to the use of Merck’s investigational and licensed pneumococcal conjugate vaccine (PCV) products, including Vaxneuvance.

• Merck to make certain milestone to Pfizer
• To make royalty payments on worldwide sales of its PCV products as follows:
  • 7.25% of net sales of all Merck PCV products through and including Dec. 31, 2026
  • 2.5% of net sales of all Merck PCV products from Jan. 1, 2027 through and including Dec. 31, 2035
• NOTE: Vaxneuvance is indicated or active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes in adults

To ...